JP2006502243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502243A5 JP2006502243A5 JP2005501197A JP2005501197A JP2006502243A5 JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5 JP 2005501197 A JP2005501197 A JP 2005501197A JP 2005501197 A JP2005501197 A JP 2005501197A JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligodeoxynucleotide
- effective
- use according
- clusterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense effect Effects 0.000 claims description 15
- 102000003780 Clusterin Human genes 0.000 claims description 9
- 108090000197 Clusterin Proteins 0.000 claims description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 201000001441 melanoma Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40519302P | 2002-08-21 | 2002-08-21 | |
| US40815202P | 2002-09-03 | 2002-09-03 | |
| US31974802P | 2002-12-02 | 2002-12-02 | |
| US47238703P | 2003-05-20 | 2003-05-20 | |
| PCT/CA2003/001276 WO2004018675A1 (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006502243A JP2006502243A (ja) | 2006-01-19 |
| JP2006502243A5 true JP2006502243A5 (enExample) | 2007-11-08 |
| JP4620585B2 JP4620585B2 (ja) | 2011-01-26 |
Family
ID=31950766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501197A Expired - Fee Related JP4620585B2 (ja) | 2002-08-21 | 2003-08-21 | クラステリンレベルを減少させることによる黒色腫の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7285541B2 (enExample) |
| EP (1) | EP1530636B1 (enExample) |
| JP (1) | JP4620585B2 (enExample) |
| KR (1) | KR101052289B1 (enExample) |
| AT (1) | ATE478142T1 (enExample) |
| AU (1) | AU2003258425B2 (enExample) |
| CA (1) | CA2494764C (enExample) |
| CY (1) | CY1110936T1 (enExample) |
| DE (1) | DE60333839D1 (enExample) |
| DK (1) | DK1530636T3 (enExample) |
| IL (1) | IL166657A (enExample) |
| NO (1) | NO333254B1 (enExample) |
| NZ (1) | NZ538288A (enExample) |
| PT (1) | PT1530636E (enExample) |
| SI (1) | SI1530636T1 (enExample) |
| WO (1) | WO2004018675A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100820266B1 (ko) | 1999-02-26 | 2008-04-08 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| KR101166214B1 (ko) | 2002-01-17 | 2012-07-16 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법 |
| CA2882443C (en) | 2002-08-21 | 2016-12-13 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
| DE60333839D1 (de) | 2002-08-21 | 2010-09-30 | Univ British Columbia | Behandlung von melanomen durch reduktion der clusterin menge |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| CA2560269A1 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
| US20080014198A1 (en) * | 2004-11-23 | 2008-01-17 | The University Of British Columbia | Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| AU2008293138A1 (en) * | 2007-08-28 | 2009-03-05 | Auckland Uniservices Limited | Cell marker of melanocyte cell lineage and uses thereof |
| HRP20191129T1 (hr) | 2009-11-24 | 2019-09-20 | Alethia Biotherapeutics Inc. | Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora |
| MX2013010524A (es) | 2011-03-15 | 2013-12-06 | Univ British Columbia | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. |
| HK1201555A1 (en) | 2011-10-25 | 2015-09-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
| EA201491568A1 (ru) | 2012-02-22 | 2014-11-28 | Алетиа Байотерапьютикс Инк. | Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака |
| WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| CA2900533A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Anti-clusterin monotherapy for cancer treatment |
| WO2023147417A2 (en) * | 2022-01-26 | 2023-08-03 | Idexx Laboratories, Inc. | Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5646042A (en) | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| AUPM672594A0 (en) | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| CA2323929C (en) * | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6464975B2 (en) | 1998-12-11 | 2002-10-15 | The Research Foundation Of State University Of New York | Compositions and methods for altering cell migration |
| KR100820266B1 (ko) | 1999-02-26 | 2008-04-08 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| AU2730801A (en) | 1999-12-21 | 2001-07-03 | Yale University | Survivin promotion of angiogenesis |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| KR101166214B1 (ko) * | 2002-01-17 | 2012-07-16 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법 |
| DE60333839D1 (de) | 2002-08-21 | 2010-09-30 | Univ British Columbia | Behandlung von melanomen durch reduktion der clusterin menge |
| CA2882443C (en) | 2002-08-21 | 2016-12-13 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US8061408B2 (en) | 2009-10-13 | 2011-11-22 | Varel Europe S.A.S. | Casting method for matrix drill bits and reamers |
-
2003
- 2003-08-21 DE DE60333839T patent/DE60333839D1/de not_active Expired - Lifetime
- 2003-08-21 JP JP2005501197A patent/JP4620585B2/ja not_active Expired - Fee Related
- 2003-08-21 US US10/646,391 patent/US7285541B2/en not_active Expired - Fee Related
- 2003-08-21 KR KR1020057002964A patent/KR101052289B1/ko not_active Expired - Fee Related
- 2003-08-21 AT AT03792074T patent/ATE478142T1/de active
- 2003-08-21 EP EP03792074A patent/EP1530636B1/en not_active Expired - Lifetime
- 2003-08-21 SI SI200331891T patent/SI1530636T1/sl unknown
- 2003-08-21 CA CA2494764A patent/CA2494764C/en not_active Expired - Fee Related
- 2003-08-21 NZ NZ538288A patent/NZ538288A/en not_active IP Right Cessation
- 2003-08-21 DK DK03792074.1T patent/DK1530636T3/da active
- 2003-08-21 PT PT03792074T patent/PT1530636E/pt unknown
- 2003-08-21 AU AU2003258425A patent/AU2003258425B2/en not_active Ceased
- 2003-08-21 WO PCT/CA2003/001276 patent/WO2004018675A1/en not_active Ceased
-
2005
- 2005-02-02 IL IL166657A patent/IL166657A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051426A patent/NO333254B1/no not_active IP Right Cessation
-
2010
- 2010-11-19 CY CY20101101046T patent/CY1110936T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502243A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| JP6649248B2 (ja) | 細胞取り込みの向上のための化合物および方法 | |
| DK2850186T3 (en) | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION | |
| AU2014306284B2 (en) | Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| CN113164509A (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| WO2013173637A1 (en) | Compositions and methods for modulating gene expression | |
| JP6487913B2 (ja) | 成長ホルモン受容体のモジュレータ | |
| KR20130106811A (ko) | 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법 | |
| CA2873769A1 (en) | Compositions and methods for modulating hemoglobin gene family expression | |
| JP2004509970A5 (enExample) | ||
| EA035756B1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| JP2018530325A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2016513976A5 (enExample) | ||
| CN113293163A (zh) | 用于调节载脂蛋白c-iii表达的组合物和方法 | |
| JP2010512747A5 (enExample) | ||
| JP2003531915A (ja) | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 | |
| KR20150004414A (ko) | Kras-관련 질환을 치료하기 위한 유기 조성물 | |
| KR20130051954A (ko) | 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물 | |
| CN110536965B (zh) | 用于抑制男性型脱发靶基因表达的不对称siRNA | |
| JP2008520591A5 (enExample) | ||
| JPWO2003025173A1 (ja) | Ｃ型肝炎ウイルスに対する新規なアンチセンスオリゴヌクレオチド誘導体 | |
| JPWO2021010301A5 (enExample) |